Meanwhile, the ﻿combination of chemotherapy and gefitinib also provided a better survival benefit than gefitinib monotherapy for patients with lung adenocarcinoma harboring EGFR mutations by first using cytotoxic drug on day 1 and gefitinib from day 5–21 [39]. This evidence concerns the gene EGFR and lung adenocarcinoma.